Novel immunotherapeutic approaches for head and neck squamous cell carcinoma

Darrin V. Bann, Daniel G. Deschler, Neerav Goyal

Research output: Contribution to journalReview article

15 Citations (Scopus)

Abstract

The immune system plays a key role in preventing tumor formation by recognizing and destroying malignant cells. For over a century, researchers have attempted to harness the immune response as a cancer treatment, although this approach has only recently achieved clinical success. Head and neck squamous cell carcinoma (HNSCC) is the sixth most common cancer worldwide and is associated with cigarette smoking, alcohol consumption, betel nut use, and human papillomavirus infection. Unfortunately, worldwide mortality from HNSCC remains high, partially due to limits on therapy secondary to the significant morbidity associated with current treatments. Therefore, immunotherapeutic approaches to HNSCC treatment are attractive for their potential to reduce morbidity while improving survival. However, the application of immunotherapies to this disease has been challenging because HNSCC is profoundly immunosuppressive, resulting in decreased absolute lymphocyte counts, impaired natural killer cell function, reduced antigen-presenting cell function, and a tumor-permissive cytokine profile. Despite these challenges, numerous clinical trials testing the safety and efficacy of immunotherapeutic approaches to HNSCC treatment are currently underway, many of which have produced promising results. This review will summarize immunotherapeutic approaches to HNSCC that are currently undergoing clinical trials.

Original languageEnglish (US)
Article number87
JournalCancers
Volume8
Issue number10
DOIs
StatePublished - Oct 1 2016

Fingerprint

Neoplasms
Clinical Trials
Areca
Morbidity
Therapeutics
Papillomavirus Infections
Lymphocyte Count
Antigen-Presenting Cells
Immunosuppressive Agents
Natural Killer Cells
Alcohol Drinking
Immunotherapy
Carcinoma, squamous cell of head and neck
Immune System
Smoking
Research Personnel
Cytokines
Safety
Survival
Mortality

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Bann, Darrin V. ; Deschler, Daniel G. ; Goyal, Neerav. / Novel immunotherapeutic approaches for head and neck squamous cell carcinoma. In: Cancers. 2016 ; Vol. 8, No. 10.
@article{c8b6d8cd0602426b826954f978e5cfac,
title = "Novel immunotherapeutic approaches for head and neck squamous cell carcinoma",
abstract = "The immune system plays a key role in preventing tumor formation by recognizing and destroying malignant cells. For over a century, researchers have attempted to harness the immune response as a cancer treatment, although this approach has only recently achieved clinical success. Head and neck squamous cell carcinoma (HNSCC) is the sixth most common cancer worldwide and is associated with cigarette smoking, alcohol consumption, betel nut use, and human papillomavirus infection. Unfortunately, worldwide mortality from HNSCC remains high, partially due to limits on therapy secondary to the significant morbidity associated with current treatments. Therefore, immunotherapeutic approaches to HNSCC treatment are attractive for their potential to reduce morbidity while improving survival. However, the application of immunotherapies to this disease has been challenging because HNSCC is profoundly immunosuppressive, resulting in decreased absolute lymphocyte counts, impaired natural killer cell function, reduced antigen-presenting cell function, and a tumor-permissive cytokine profile. Despite these challenges, numerous clinical trials testing the safety and efficacy of immunotherapeutic approaches to HNSCC treatment are currently underway, many of which have produced promising results. This review will summarize immunotherapeutic approaches to HNSCC that are currently undergoing clinical trials.",
author = "Bann, {Darrin V.} and Deschler, {Daniel G.} and Neerav Goyal",
year = "2016",
month = "10",
day = "1",
doi = "10.3390/cancers8100087",
language = "English (US)",
volume = "8",
journal = "Cancers",
issn = "2072-6694",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "10",

}

Novel immunotherapeutic approaches for head and neck squamous cell carcinoma. / Bann, Darrin V.; Deschler, Daniel G.; Goyal, Neerav.

In: Cancers, Vol. 8, No. 10, 87, 01.10.2016.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Novel immunotherapeutic approaches for head and neck squamous cell carcinoma

AU - Bann, Darrin V.

AU - Deschler, Daniel G.

AU - Goyal, Neerav

PY - 2016/10/1

Y1 - 2016/10/1

N2 - The immune system plays a key role in preventing tumor formation by recognizing and destroying malignant cells. For over a century, researchers have attempted to harness the immune response as a cancer treatment, although this approach has only recently achieved clinical success. Head and neck squamous cell carcinoma (HNSCC) is the sixth most common cancer worldwide and is associated with cigarette smoking, alcohol consumption, betel nut use, and human papillomavirus infection. Unfortunately, worldwide mortality from HNSCC remains high, partially due to limits on therapy secondary to the significant morbidity associated with current treatments. Therefore, immunotherapeutic approaches to HNSCC treatment are attractive for their potential to reduce morbidity while improving survival. However, the application of immunotherapies to this disease has been challenging because HNSCC is profoundly immunosuppressive, resulting in decreased absolute lymphocyte counts, impaired natural killer cell function, reduced antigen-presenting cell function, and a tumor-permissive cytokine profile. Despite these challenges, numerous clinical trials testing the safety and efficacy of immunotherapeutic approaches to HNSCC treatment are currently underway, many of which have produced promising results. This review will summarize immunotherapeutic approaches to HNSCC that are currently undergoing clinical trials.

AB - The immune system plays a key role in preventing tumor formation by recognizing and destroying malignant cells. For over a century, researchers have attempted to harness the immune response as a cancer treatment, although this approach has only recently achieved clinical success. Head and neck squamous cell carcinoma (HNSCC) is the sixth most common cancer worldwide and is associated with cigarette smoking, alcohol consumption, betel nut use, and human papillomavirus infection. Unfortunately, worldwide mortality from HNSCC remains high, partially due to limits on therapy secondary to the significant morbidity associated with current treatments. Therefore, immunotherapeutic approaches to HNSCC treatment are attractive for their potential to reduce morbidity while improving survival. However, the application of immunotherapies to this disease has been challenging because HNSCC is profoundly immunosuppressive, resulting in decreased absolute lymphocyte counts, impaired natural killer cell function, reduced antigen-presenting cell function, and a tumor-permissive cytokine profile. Despite these challenges, numerous clinical trials testing the safety and efficacy of immunotherapeutic approaches to HNSCC treatment are currently underway, many of which have produced promising results. This review will summarize immunotherapeutic approaches to HNSCC that are currently undergoing clinical trials.

UR - http://www.scopus.com/inward/record.url?scp=84991218654&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84991218654&partnerID=8YFLogxK

U2 - 10.3390/cancers8100087

DO - 10.3390/cancers8100087

M3 - Review article

C2 - 27669306

AN - SCOPUS:84991218654

VL - 8

JO - Cancers

JF - Cancers

SN - 2072-6694

IS - 10

M1 - 87

ER -